Abstract
The serendipitous discovery of phencyclidine (PCP) in 1956 sets the stage for significant research efforts that resulted in a plethora of analogs and derivatives designed to explore the biological effects of this class. PCP soon became the prototypical dissociative agent that eventually sneaked through the doors of clinical laboratories and became an established street drug. Estimations suggest that around 14 PCP analogs were identified as “street drugs” in the period between the 1960s and 1990s. Fast forward to the 2000s, and largely facilitated by advancements in electronic forms of communication made possible through the Internet, a variety of new PCP analogs began to attract the attention of communities interested in the collaborative exploration of these substances. Traditionally, as was the case with the first-generation analogs identified in previous decades, the substances explored represented compounds already known in the scientific literature. As the decade of the noughties unfolded, a number of new PCP-derived substances appeared on the scene, which included some analogs that have not been previously recorded in the published literature. The aim of this chapter is to present a brief introductory overview of substances that have materialized as PCP-derived new psychoactive substances (NPS) in recent years and their known pharmacology. Since N-methyl-d-aspartate receptor (NMDAR) antagonism is implicated in mediating the subjective and mind-altering effects of many dissociative drugs, additional data are included from other analogs not presently identified as NPS.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- 2-MeO-PCMo:
-
4-[1-(2-Methoxyphenyl)cyclohexyl]morpholine
- 3,4-MD-PCE:
-
1-(1,3-Benzodioxol-5-yl)-N-ethylcyclohexanamine
- 3,4-MD-PCMo:
-
4-[1-(1,3-Benzodioxol-5-yl)cyclohexyl]morpholine
- 3,4-MD-PCPr:
-
1-(1,3-Benzodioxol-5-yl)-N-propylcyclohexanamine
- 3,4-MD-PCPy:
-
1-[1-(1,3-Benzodioxol-5-yl)cyclohexyl]pyrrolidine
- 3-HO-PCE:
-
3-[1-(Ethylamino)cyclohexyl]phenol
- 3-HO-PCMe:
-
1-3-Hydroxyphenyl)-N-methylcyclohexanamine
- 3-HO-PCP:
-
3-[1-(Piperidin-1-yl)cyclohexyl]phenol
- 3-HO-PCPr:
-
1-3-Hydroxyphenyl)-N-propylcyclohexanamine
- 3-Me-4-F-PCP:
-
1-[1-(4-Fluoro-3-methylphenyl)cyclohexyl]piperidine
- 3-Me-4-MeO-PCP:
-
1-[1-(4-Methoxy-3-methylphenyl)cyclohexyl]piperidine
- 3-MeO-PCE:
-
N-Ethyl-1-(3-methoxyphenyl)cyclohexan-1-amine
- 3-MeO-PCMe:
-
1-(3-Methoxyphenyl)-N-methylcyclohexan-1-amine
- 3-MeO-PCMMo:
-
4-{[1-(3-Methoxyphenyl)cyclohexyl]methyl}morpholine
- 3-MeO-PCMo:
-
4-[1-(3-Methoxyphenyl)cyclohexyl]morpholine
- 3-MeO-PCP:
-
1-[1-(3-Methoxyphenyl)cyclohexyl]piperidine
- 3-MeO-PCPr:
-
1-(3-Methoxyphenyl)-N-propylcyclohexan-1-amine
- 3-MeO-PCPy:
-
1-[1-(3-Methoxyphenyl)cyclohexyl]pyrrolidine
- 3-Me-PCMo:
-
4-[1-(3-Methylphenyl)cyclohexyl]morpholine
- 3-Me-PCPMe:
-
N-Methyl-1-(3-methylphenyl)cyclohexanamine
- 3-Me-PCPy:
-
1-[1-(3-Methylphenyl)cyclohexyl]pyrrolidine
- 4′-Me-PCP:
-
1-(4-Methyl-1-phenylcyclohexyl)piperidine
- 4-MeO-PCMo:
-
4-[1-(4-Methoxyphenyl)cyclohexyl]morpholine
- 4-MeO-PCP:
-
1-[1-(4-Methoxyphenyl)cyclohexyl]piperidine (methoxydine)
- 4-MeO-PCPy:
-
1-[1-(4-Methoxyphenyl)cyclohexyl]pyrrolidine
- 4-Me-PCP:
-
1-[1-(4-Methylphenyl)cyclohexyl]piperidine
- AB-FUBINACA:
-
N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
- BnCP:
-
1-(1-Benzylcyclohexyl)piperidine
- DXM:
-
Dextromethorphan
- MDPV:
-
1-(2H-1,3-Benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one
- MK-801:
-
(+)-10,11-Dihydro-5H-5,10-epiminodibenzo[a,d][7]annulene (dizocilpine)
- MXE:
-
2-(Ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine)
- PCE:
-
N-Ethyl-1-phenylcyclohexan-1-amine (eticyclidine)
- PCEEA:
-
N-(2-Ethoxyethyl)-1-phenylcyclohexan-1-amine
- PCHOEA:
-
2-[(1-Phenylcyclohexyl)amino]ethan-1-ol
- PCiP:
-
1-Phenyl-N-(propan-2-yl)cyclohexan-1-amine
- PCMEA:
-
N-(2-Methoxyethyl)-1-phenylcyclohexan-1-amine
- PCMo:
-
4-(1-Phenylcyclohexyl)morpholine
- PCMPA:
-
N-(3-Methoxypropyl)-1-phenylcyclohexan-1-amine
- PCP:
-
1-(1-Phenylcyclohexyl)piperidine (phencyclidine)
- PCPr:
-
1-Phenyl-N-propylcyclohexan-1-amine
- PCPy:
-
1-(1-Phenylcyclohexyl)pyrrolidine (rolicyclidine)
- TCP:
-
1-[1-(Thiophen-2-yl)cyclohexyl]piperidine (tenocyclidine)
- TCPy:
-
1-[1-(Thiophen-2-yl)cyclohexyl]pyrrolidine
- U-49900:
-
3,4-Dichloro-N-[(1R,2R)-2-(diethylamino)cyclohexyl]-N-methylbenzamide
References
Aguayo LG, Albuquerque EX (1986) Effects of phencyclidine and its analogs on the end-plate current of the neuromuscular junction. J Pharmacol Exp Ther 239:15–24
Ahmadi A, Khalili M, Hajikhani R, Naserbakht M (2011a) New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats. Pharmacol Biochem Behav 98:227–233
Ahmadi A, Khalili M, Hajikhani R, Naserbakht M (2011b) Synthesis and determination of acute and chronic pain activities of 1-[1-(4-methylphenyl) (cyclohexyl)] morpholine as a new phencyclidine derivative in rats. Arzneimittelforschung 61:92–97
Allard S, Deslandes G, Gaborit B, Lomenech H, Pineau A, Jolliet P, Garret C, Monteil-Ganiere C (2017) 3-MeO-PCP et 4-MeO-PCP: confusion des isomères et risque majeur de toxicité. Toxicol Anal Clin 29:S47–S48
Aniline O, Pitts FN Jr (1982) Phencyclidine (PCP): a review and perspectives. Crit Rev Toxicol 10:145–177
Anonymous (1960) Cyclohexylamine compounds and methods for producing the same. Patent no. GB851782. Parke-Davis, Detroit
Anonymous (2008) Bluelight. Thread: the Big & Dandy 4-MeO-PCP thread. http://bluelight.org/vb/threads/391328-The-Big-amp-Dandy-4-MeO-PCP-Thread. Accessed 3 Feb 2018
Anonymous (2012a) Bluelight. Psychedelic drugs. Thread: 3-ho-pcp. http://www.bluelight.org/vb/threads/623701-3-ho-pcp. Accessed 3 Feb 2018
Anonymous (2012b) Bluelight. Trip reports. Thread: a trial with 3-OH-PCP. http://www.bluelight.org/vb/threads/633737-3-HO-PCE-fumarate. Accessed 3 Feb 2018
Anonymous (2015a) 3-MeO-PCP’s little brother: an experience with 3-MeO-PCMo (exp106299). Erowid.org. 28 Aug 2015. https://erowid.org/experiences/exp_pdf.php?ID=106299&format=pdf. Accessed 3 Feb 2018
Anonymous (2015b) A novel dissociative but not a novel feeling: an experience with 3-MeO-PCMo (exp106459). Erowid.org. 28 Aug 2015. https://erowid.org/experiences/exp_pdf.php?ID=106459&format=pdf. Accessed 3 Feb 2018
Anonymous (2015c) UK chemical research, chemical discussion, psychedelics, 3-MeO-PCMo. https://www.ukchemicalresearch.org/Thread-3-MeO-PCMo. Accessed 3 Feb 2018
Anonymous (2017) Bluelight. Psychedelic drugs. Thread: the big & Dandy 3-HO-PCE thread. http://bluelight.org/vb/threads/812314-The-Big-amp-Dandy-3-HO-PCE-Thread. Accessed 3 Feb 2018
Anonymous (2018a) Bluelight psychedelic drugs index. Thread. Novel dissociative 3-MeO-PCMo. http://www.bluelight.org/vb/threads/758083-Novel-dissociative-3-MeO-PCMo. Accessed 3 Feb 2018
Anonymous (2018b) Erowid experience vaults report Id: 110467. Accessed 3 Feb 2018
Backberg M, Beck O, Helander A (2015) Phencyclidine analog use in Sweden–intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. Clin Toxicol (Phila) 53:856–864
Bakota E, Arndt C, Romoser AA, Wilson SK (2016) Fatal intoxication involving 3-MeO-PCP: a case report and validated method. J Anal Toxicol 40:504–510
Balster RL, Chait LD (1976) The behavioral pharmacology of phencyclidine. Clin Toxicol (Phila) 9:513–528
Balster RL, Woolverton WL (1980) Continuous-access phencyclidine self-administration by rhesus monkeys leading to physical dependence. Psychopharmacology 70:5–10
Barceloux DG (2012) Phencyclidine and phencyclidine analogues. In: Barceloux DG (ed) Medical toxicology of drugs abuse: synthesized chemicals and psychoactive plants. Wiley, Hoboken, pp 608–632
Baselt RC (2011) Disposition of toxic drugs and chemicals in man, 9th edn. Biomedical Publications, Seal Beach, pp 1323–1325
Bertol E, Pascali J, Palumbo D, Catalani V, Di Milia MG, Fioravanti A, Mari F, Vaiano F (2017) 3-MeO-PCP intoxication in two young men: first in vivo detection in Italy. Forensic Sci Int 274:7–12
Bey T, Patel A (2007) Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug. Cal J Emerg Med 8:9–14
Boldyrev AA, Carpenter DO, Johnson P (2005) Emerging evidence for a similar role of glutamate receptors in the nervous and immune systems. J Neurochem 95:913–918
Brady KT, Balster RL (1981) Discriminative stimulus properties of phencyclidine and five analogues in the squirrel monkey. Pharmacol Biochem Behav 14:213–218
Brine GA, Boldt KG, Coleman ML, Carroll FI (1984) Carbon-13 nuclear magnetic resonance spectra of phencyclidine analogs substituted in the piperidine and aromatic rings. J Heterocycl Chem 21:71–75
Burns RS, Lerner SE (1976) Perspectives: acute phencyclidine intoxication. Clin Toxicol 9:477–501
Cadinu D, Grayson B, Podda G, Harte MK, Doostdar N, Neill JC (2017) NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.1011.1045
Carroll FI, Brine GA, Boldt KG, Mascarella SW, Moreland CG, Sumner SJ, Burgess JP, Stejskal EO (1988) Solid state conformation of phencyclidine and phencyclidine analogs. In: Domino EF, Kamenka JM (eds) Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp 91–106
Casale JF (2011) 4-Methoxyphencyclidine: an analytical profile. Microgram J 8:39–42
Chang BN, Smith MP (2017) A case of unusual drug screening results. Clin Chem 63:958–961
Chaudieu I, Vignon J, Chicheportiche M, El Harfi A, Kamenka JM, Chicheportiche R (1987) Comparaison entre les sites de fixation de la [3H]phencyclidine (PCP) et de la [3H](thiényl-2)-1 cyclohexylpipéridine (TCP) dans le système nerveux central de rat. Eur J Med Chem 22:359–362
Chaudieu I, Vignon J, Chicheportiche M, Kamenka JM, Trouiller G, Chicheportiche R (1989) Role of the aromatic group in the inhibition of phencyclidine binding and dopamine uptake by PCP analogs. Pharmacol Biochem Behav 32:699–705
Chen G (1981) The neuropharmacology of phencyclidine. In: Domino EF (ed) PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp 9–23
Cho AK, Hallström G, Matsumotto RM, Kammerer RC (1983) The metabolism of the piperidine ring of phencyclidine. In: Kamenka JM, Domino EF, Geneste P (eds) Phencyclidine and related arylcyclohexylamines: present and future applications. NPP Books, Ann Arbor, pp 205–214
Cho AK, Hiramatsu M, Schmitz DA, Nabeshima T, Kameyama T (1991) Pharmacokinetic and pharmacodynamic properties of some phencyclidine analogs in rats. Pharmacol Biochem Behav 39:947–953
Clouet DH (1986) Phencyclidine: an update, NIDA research monograph, vol 64. United States Department of Health and Human Services, National Institute on Drug Abuse, Rockville
Colestock T, Wallach J, Mansi M, Filemban N, Morris H, Elliott SP, Westphal F, Brandt SD, Adejare A (2018) Syntheses, analytical and pharmacological characterizations of the ‘legal high’ 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues. Drug Test Anal 10:272–283
Cone EJ, McQuinn RL, Shannon HE (1984) Structure-activity relationship studies of phencyclidine derivatives in rats. J Pharmacol Exp Ther 228:147–153
Cook CE, Brine DR, Jeffcoat AR, Hill JM, Wall ME, Perez-Reyes M, Di Guiseppi SR (1982) Phencyclidine disposition after intravenous and oral doses. Clin Pharmacol Ther 31:625–634
Coppola M, Mondola R (2013) Is methoxydine a new rapid acting antidepressant for the treatment of depression in alcoholics? Med Hypotheses 81:10–14
Costa JF, Speaker TJ (1983) Chromatographic and spectral properties of some aryl-substituted phencyclidine analogs. J Anal Toxicol 7:252–256
Cravey RH, Reed D, Ragle JL (1979) Phencyclidine-related deaths: a report of nine fatal cases. J Anal Toxicol 3:199–201
Cull-Candy S, Brickley S, Farrant M (2001) NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 11:327–335
De Paoli G, Brandt SD, Wallach J, Archer RP, Pounder DJ (2013) From the street to the laboratory: analytical profiles of methoxetamine, 3-methoxyeticyclidine and 3-methoxyphencyclidine and their determination in three biological matrices. J Anal Toxicol 37:277–283
Domino EF (1964) Neurobiology of phencyclidine (Sernyl), a drug with an unusual spectrum of pharmacological activity. Int Rev Neurobiol 6:303–347
Domino EF (ed) (1981) PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor
Domino EF (2010) Taming the ketamine tiger. Anesthesiology 113:678–684
Domino EF, Kamenka JM (eds) (1988) Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor
Domino EF, Rocki W, Holsztynska EJ, Lee S (1983) Structure-activity relationships of phencyclidine derivatives and related substances on mouse motor performance. In: Kamenka JM, Domino EF, Geneste P (eds) Phencyclidine and related arylcyclohexylamines: present and future applications. NPP Books, Ann Arbor, pp 397–409
Done AK, Aronow R, Miceli JN (1978) The pharmacokinetics of phencyclidine in overdosage and its treatment. In: Petersen RC, Stillman RC (eds) Phencyclidine (PCP) abuse: an appraisal, NIDA research monograph, vol 21. United States Department of Health and Human Services, National Institute on Drug Abuse, Rockville, pp 210–217
Dresen S, Blake D, Taylor A, Williams K (2014) Identification and quantitation of designer drugs in urine by LC-MS/MS. Technical note, AB SCIEX, Framingham. https://sciex.com.cn/Documents/Applications/RUO-MKT-02-1407-A_technote_designer_drugs.pdf. Accessed 3 Feb 2018
Driscoll JP, Kornecki K, Wolkowski JP, Chupak L, Kalgutkar AS, O’Donnell JP (2007) Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate. Chem Res Toxicol 20:1488–1497
El M’Barki C, Elhallaqui M (2017) Quantum calculations to construct a 3D-QSAR model based on PCP-TCP derivatives and molecular docking with NMDA receptor. J Mater Environ Sci 8:1391–1400
EMCDDA–Europol (2011) EMCDDA–Europol 2010 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/644/EMCDDA-Europol_Annual_Report_2010A_281336.pdf. Accessed 3 Feb 2018
EMCDDA–Europol (2012) EMCDDA–Europol 2011 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/689/EMCDDA-Europol_Annual_Report_2011_2012_final_335568.pdf. Accessed 3 Feb 2018
EMCDDA–Europol (2013) New drugs in Europe, 2012. EMCDDA–Europol 2012 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/734/EMCDDA-Europol_2012_Annual_Report_final_439477.pdf. Accessed 3 Feb 2018
EMCDDA–Europol (2015) EMCDDA–Europol 2014 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/1018/TDAN15001ENN.pdf. Accessed 3 Feb 2018
EMCDDA–Europol (2016) EMCDDA–Europol 2015 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/2880/TDAS16001ENN.pdf. Accessed 3 Feb 2018
EMCDDA–Europol (2017) EMCDDA–Europol 2016 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/4724/TDAN17001ENN_PDFWEB.pdf. Accessed 3 Feb 2018
Feldman HW, Agar MH, Beschner GM (eds) (1979) Angel dust. An ethnographic study of phencyclidine users. Lexington Books, Lexington
Frohlich J, Van Horn JD (2014) Reviewing the ketamine model for schizophrenia. J Psychopharmacol 28:287–302
Gable MS, Gavali S, Radner A, Tilley DH, Lee B, Dyner L, Collins A, Dengel A, Dalmau J, Glaser CA (2009) Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis 28:1421–1429
Geneste P, Kamenka JM, Ung SN, Herrmann P, Goudal R, Trouiller G (1979) Determination conformationelle de dérivés de la phencyclidine en vue d’une correlation structure-activité. Eur J Med Chem Chim Ther 14:301–308
Giannini AJ, Castellani S (1982) A case of phenylcyclohexylpyrrolidine (PHP) intoxication treated with physostigmine. J Toxicol Clin Toxicol 19:505–508
Giannini AJ, Price WA, Loiselle RH, Malone DW (1985) Treatment of phenylcyclohexylpyrrolidine (PHP) psychosis with haloperidol. J Toxicol Clin Toxicol 23:185–189
Gintzler AR, Zukin RS, Zukin SR (1982) Effects of phencyclidine and its derivatives on enteric neurones. Br J Pharmacol 75:261–267
Giros B, El Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, Caron MG (1992) Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 42:383–390
Gole DJ, Pirat JL, Domino EF (1988a) New aspects of phencyclidine (PCP) metabolism. In: Domino EF, Kamenka JM (eds) Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp 625–641
Gole DJ, Pirat JL, Kamenka JM, Domino EF (1988b) Hydroxy metabolites of phencyclidine. Identification and quantitation of two novel metabolites. Drug Metab Dispos 16:386–391
Gole DJ, Pirat JL, Kamenka JM, Kalir A, Domino EF (1988c) Analysis of phencyclidine (PCP) and other structurally related compounds by gas chromatography-mass spectrometry (GC-MS). In: Domino EF, Kamenka JM (eds) Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp 79–89
Greifenstein FE, Devault M, Yoshitake J, Gajewski JE (1958) A study of a 1-aryl cyclo hexyl amine for anesthesia. Anesth Analg 37:283–294
Hallstrom G, Kammerer RC, Nguyen CH, Schmitz DA, Di Stefano EW, Cho AK (1983) Phencyclidine metabolism in vitro. The formation of a carbinolamine and its metabolites by rabbit liver preparations. Drug Metab Dispos 11:47–53
Hamon J, Vignon J, Kamenka JM (1996) Effect of lowered lipophilicity on the affinity of PCP analogs for the PCP receptor and the dopamine transporter. Eur J Med Chem 31:489–495
Haradahira T, Sasaki S, Maeda M, Kobayashi K, Inoue O, Tomita U, Nishikawa T, Suzuki K (1998) Synthesis and brain distribution of carbon-11 labeled analogs of antagonists for the NMDA receptor coupled PCP-binding site. J Label Compd Radiopharm 41:843–858
Hardingham GE, Bading H (2003) The Yin and Yang of NMDA receptor signalling. Trends Neurosci 26:81–89
Haring R, Theomy S, Kalir A, Sokolovsky M (1983) Characterization of the interaction of phencyclidine and its derivatives with the ionic channel of the nicotinic receptor. In: Chambers CM, Chambers PL, Gitter S (eds) Toxicology in the use, misuse, and abuse of food, drugs, and chemicals, Archives of Toxicology (supplement), vol 6. Springer, Berlin, pp 81–90
Hearne E, Van Hout MC (2016) “Trip-sitting” in the black hole: a netnographic study of dissociation and indigenous harm reduction. J Psychoactive Drugs 48:233–242
Holsztynska EJ, Domino EF (1983) Overview of phencyclidine biotransformation. In: Kamenka JM, Domino EF, Geneste P (eds) Phencyclidine and related arylcyclohexylamines: present and future applications. NPP Books, Ann Arbor, pp 157–194
Holsztynska EJ, Domino EF (1985) Biotransformation of phencyclidine. Drug Metab Rev 16:285–320
Hori T, Suzuki T, Baba A, Abe S, Yamamoto T, Moroji T, Shiraishi H (1996) Effects of phencyclidine metabolites on serotonin uptake in rat brain. Neurosci Lett 209:153–156
Hundt W, Danysz W, Holter SM, Spanagel R (1998) Ethanol and N-methyl-D-aspartate receptor complex interactions: a detailed drug discrimination study in the rat. Psychopharmacology (Berl) 135:44–51
Itzhak Y (1988) Pharmacological specificity of some psychotomimetic and antipsychotic agents for the sigma and PCP binding sites. Life Sci 42:745–752
Itzhak Y, Kalir A, Sarne Y (1981a) On the opioid nature of phencyclidine and its 3-hydroxy derivative. Eur J Pharmacol 73:229–233
Itzhak Y, Kalir A, Weissman BA, Cohen S (1981b) Receptor binding and antinociceptive properties of phencyclidine opiate-like derivatives. Eur J Pharmacol 72:305–311
Jackson JE (1989) Phencyclidine pharmacokinetics after a massive overdose. Ann Intern Med 111:613–615
Javitt DC (2007) Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78:69–108
Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301–1308
Johansson A, Lindstedt D, Roman M, Thelander G, Nielsen EI, Lennborn U, Sandler H, Rubertsson S, Ahlner J, Kronstrand R, Kugelberg FC (2017) A non-fatal intoxication and seven deaths involving the dissociative drug 3-MeO-PCP. Forensic Sci Int 275:76–82
Johnson N, Itzhak Y, Pasternak GW (1984) Interaction of two phencyclidine opiate-like derivatives with 3H-opioid binding sites. Eur J Pharmacol 101:281–284
Jordan S, Chen R, Fernalld R, Johnson J, Regardie K, Kambayashi J, Tadori Y, Kitagawa H, Kikuchi T (2006) In vitro biochemical evidence that the psychotomimetics phencyclidine, ketamine and dizocilpine (MK-801) are inactive at cloned human and rat dopamine D2 receptors. Eur J Pharmacol 540:53–56
Kalir A (1981) Structure activity relationships of phencyclidine derivatives. In: Domino EF (ed) PCP (phencyclidine), historical and current perspectives. NPP Books, Ann Arbor, pp 31–46
Kalir A, Edery H, Pelah Z, Balderman D, Porath G (1969) 1-Phenylcycloalkylamine derivatives. II. Synthesis and pharmacological activity. J Med Chem 12:473–477
Kalir A, Elkavets R, Pri-Bar I, Buchman O (1978) Structure-activity relationship of some phencyclidine derivatives: in vivo studies in mice. Eur J Med Chem Chim Ther 13:17–24
Kamenka JM, Geneste P (1981) Synthesis, conformation, and physical properties of phencyclidine and its derivatives. In: Domino EF (ed) PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp 47–82
Kamenka JM, Geneste P (1983) The biologically active conformation of PCP and its consequences: a hypothesis. In: Kamenka JM, Domino EF, Geneste P (eds) Phencyclidine and related arylcyclohexylamines: present and future applications. NPP Books, Ann Arbor, pp 1–12
Kamenka JM, Chiche B, Goudal R, Geneste P, Vignon J, Vincent JP, Lazdunski M (1982) Chemical synthesis and molecular pharmacology of hydroxylated 1-(1-phenylcyclohexyl-piperidine derivatives. J Med Chem 25:431–435
Kammerer RC, Schmitz DA, Hwa JJ, Cho AK (1984) Induction of phencyclidine metabolism by phencyclidine, ketamine, ethanol, phenobarbital and isosafrole. Biochem Pharmacol 33:599–604
Kapur S, Seeman P (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors-implications for models of schizophrenia. Mol Psychiatry 7:837–844
Karakas E, Furukawa H (2014) Crystal structure of a heterotetrameric NMDA receptor ion channel. Science 344:992–997
Kemp JA, McKernan RM (2002) NMDA receptor pathways as drug targets. Nat Neurosci 5(Suppl):1039–1042
Kozlowski MR, Browne RG, Vinick FJ (1986) Discriminative stimulus properties of phencyclidine (PCP)-related compounds: correlations with 3H-PCP binding potency measured autoradiographically. Pharmacol Biochem Behav 25:1051–1058
Krotulski AJ, Papsun DM, Friscia M, Swartz JL, Holsey BD, Logan BK (2017) Fatality following ingestion of tetrahydrofuranylfentanyl, U-49900 and methoxy-phencyclidine. J Anal Toxicol 42:e27–e32
Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, Stetson P, Trevisan LA, Charney DS (1998) Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry 55:354–360
Krystal JH, Petrakis IL, Krupitsky E, Schutz C, Trevisan L, D’Souza DC (2003) NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy. Ann N Y Acad Sci 1003:176–184
Largent BL, Gundlach AL, Snyder SH (1986) Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047, (+)-[3H]-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine and [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine. J Pharmacol Exp Ther 238:739–748
Leander JD, Rathbun RC, Zimmerman DM (1988) Anticonvulsant effects of phencyclidine-like drugs: relation to N-methyl-D-aspartic acid antagonism. Brain Res 454:368–372
Leccese AP, Marquis KL, Mattia A, Moreton JE (1986) The convulsant and anticonvulsant effects of phencyclidine (PCP) and PCP analogues in the rat. Behav Brain Res 19:163–169
Lee CH, Lu W, Michel JC, Goehring A, Du J, Song X, Gouaux E (2014) NMDA receptor structures reveal subunit arrangement and pore architecture. Nature 511:191–197
Lehmann S, Kieliba T, Beike J, Thevis M, Mercer-Chalmers-Bender K (2017) Determination of 74 new psychoactive substances in serum using automated in-line solid-phase extraction-liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 1064:124–138
Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5:160–170
Lodge D, Mercier MS (2015) Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol 172:4254–4276
Lomenech H, Schreck B, Caillet P, Ganiere C, Allard S, Jolliet P, Victorri-Vigneau C (2017) Coma following AB-FUBINACA and 3-MeO-PCP consumption: a case report [poster abstract]. Fundam Clin Pharmacol 31:S55
Lü W et al (2017) Cryo-EM structures of the triheteromeric NMDA receptor and its allosteric modulation. Science 355(6331):eaal3729
Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959) Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 81:363–369
Maayani S, Weinstein H, Ben-zvi N, Cohen S, Sokolovsky M (1974) Psychotomimetics as anticholinergic agents. I. 1-Cyclohexylpiperidine derivatives. Anticholinesterase activity and antagonistic activity to acetylcholine. Biochem Pharmacol 23:1263–1281
Maddox VH, Godefroi EF, Parcell RF (1965) The synthesis of phencyclidine and other 1-arylcyclohexylamines. J Med Chem 8:230–235
Marquis KL, Moreton JE (1987) Animal models of intravenous phencyclinoid self-administration. Pharmacol Biochem Behav 27:385–389
McCarron MM, Schulze BW, Thompson GA, Conder MC, Goetz WA (1981) Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. Ann Emerg Med 10:237–242
McIntyre IM, Trochta A, Gary RD, Storey A, Corneal J, Schaber B (2015) A fatality related to two novel hallucinogenic compounds: 4-methoxyphencyclidine and 4-hydroxy-N-methyl-N-ethyltryptamine. J Anal Toxicol 39:751–755
McMillan DE, Evans EB, Wessinger WD, Owens SM (1988) Structure-activity relationships of arylcyclohexylamines as discriminative stimuli in pigeons. J Pharmacol Exp Ther 247:1086–1092
Mendelsohn LG, Kerchner GA, Kalra V, Zimmerman DM, Leander JD (1984) Phencyclidine receptors in rat brain cortex. Biochem Pharmacol 33:3529–3535
Meyer JS, Greifenstein F, Devault M (1959) A new drug causing symptoms of sensory deprivation. Neurological, electroencephalographic and pharmacological effects of Sernyl. J Nerv Ment Dis 129:54–61
Michely JA, Manier SK, Caspar AT, Brandt SD, Wallach J, Maurer HH (2017) New psychoactive substances 3-methoxyphencyclidine (3-MeO-PCP) and 3-methoxyrolicyclidine (3-MeO-PCPy): metabolic fate elucidated with rat urine and human liver preparations and their detectability in urine by GC-MS, “LC-(high resolution)-MSn” and “LC-(high resolution)-MS/MS”. Curr Neuropharmacol 15:692–712
Misselbrook GP, Hamilton EJ (2012) Out with the old, in with the new? Case reports of the clinical features and acute management of two novel designer drugs. Acute Med 11:157–160
Mitchell-Mata C, Thomas B, Peterson B, Couper F (2017) Two fatal intoxications involving 3-methoxyphencyclidine. J Anal Toxicol 41:503–507
Morris H, Wallach J (2014) From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal 6:614–632
Murray JB (2002) Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research. J Psychol 136:319–327
Nishimura M, Sato K, Okada T, Yoshiya I, Schloss P, Shimada S, Tohyama M (1998) Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology 88:768–774
Ogden KK, Traynelis SF (2011) New advances in NMDA receptor pharmacology. Trends Pharmacol Sci 32:726–733
Ohta S, Masumoto H, Takeuchi K, Hirobe M (1987) A phenolic metabolite of phencyclidine: the formation of a pharmacologically active metabolite by rat liver microsomes. Drug Metab Dispos 15:583–584
Paoletti P, Bellone C, Zhou Q (2013) NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 14:383–400
Petersen RC, Stillman RC (1978) Phencyclidine (PCP) abuse: an appraisal, NIDA research monograph, vol 21. United States Department of Health and Human Services, National Institute on Drug Abuse, Rockville
Pollard JC, Uhr L, Stern E (1965) Drugs and phantasy: the effects of LSD, psilocybin, and Sernyl on college students. Little, Brown, Boston
Ponchant M, Dreux Y, Kamenka JM, Chicheportiche R, Beaucourt JP (1990) Synthesis of iodine-125-labeled 3-[125I]-iodophencyclidine for biological studies. J Label Compd Radiopharm 28:1059–1064
Pradhan SN (1984) Phencyclidine (PCP): some human studies. Neurosci Biobehav Rev 8:493–501
Quirion R, Hammer RP Jr, Herkenham M, Pert CB (1981) Phencyclidine (angel dust)/sigma “opiate” receptor: visualization by tritium-sensitive film. Proc Natl Acad Sci U S A 78:5881–5885
Reel JK, Leander JD, Mendelsohn LG, Schoepp DD, Ornstein PL, Evrard DA, Hermann RB, Zimmerman DM (1988) The search for a PCP antagonist: synthesis and characterization of novel arylcyclohexylamine derivatives. In: Domino EF, Kamenka JM (eds) Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp 27–33
Risner ME (1982) Intravenous self-administration of phencyclidine and related compounds in the dog. J Pharmacol Exp Ther 221:637–644
Rogawski MA, Thurkauf A, Yamaguchi S, Rice KC, Jacobson AE, Mattson MV (1989) Anticonvulsant activities of 1-phenylcyclohexylamine and its conformationally restricted analog 1,1-pentamethylenetetrahydroisoquinoline. J Pharmacol Exp Ther 249:708–712
Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L (2013) The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS One 8:e59334
Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L (2018) Correction: the ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS One 13:e0194984
Seeman P, Ko F, Tallerico T (2005) Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 10:877–883
Shannon HE (1981a) Discriminative stimulus effects of phencyclidine: structure-activity relationships. In: Domino EF (ed) PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp 311–335
Shannon HE (1981b) Evaluation of phencyclidine analogs on the basis of their discriminative stimulus properties in the rat. J Pharmacol Exp Ther 216:543–551
Shannon HE, DeGregorio CM (1981) Effects of N-substituted analogs and metabolites of phencyclidine on avoidance behavior in the rat. J Pharmacol Exp Ther 218:55–62
Shao L, Hewitt MC, Wang F, Malcolm SC, Ma J, Campbell JE, Campbell UC, Engel SR, Spicer NA, Hardy LW, Schreiber R, Spear KL, Varney MA (2011) Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor. Bioorg Med Chem Lett 21:1438–1441
Showalter CV, Thornton WE (1977) Clinical pharmacology of phencyclidine toxicity. Am J Psychiatry 134:1234–1238
Shulgin AT, MacLean DE (1976) Illicit synthesis of phencyclidine (PCP) and several of its analogs. Clin Toxicol 9:553–560
Siegel RK (1978) Phencyclidine and ketamine intoxication: a study of four populations of recreational users. In: Petersen RC, Stillman RC (eds) Phencyclidine (PCP) abuse: an appraisal, NIDA research monograph, vol 21. United States Department of Health and Human Services, National Institute on Drug Abuse, Rockville, pp 119–147
Smith RC, Meltzer HY, Arora RC, Davis JM (1977) Effects of phencyclidine on [3H]catecholamine and [3H]serotonin uptake in synaptosomal preparations from rat brain. Biochem Pharmacol 26:1435–1439
Stefek M, Ransom RW, DiStefano EW, Cho AK (1990) The alpha carbon oxidation of some phencyclidine analogues by rat tissue and its pharmacological implications. Xenobiotica 20:591–600
Steinpreis RE (1996) The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Behav Brain Res 74:45–55
Stevenson R, Tuddenham L (2014) Novel psychoactive substance intoxication resulting in attempted murder. J Forensic Legal Med 25:60–61
Stillman R, Petersen RC (1979) The paradox of phencyclidine (PCP) abuse. Ann Intern Med 90:428–430
Suzuki T, Yamamoto T, Hori T, Baba A, Shiraishi H, Ito T, Piletz JE, Ho IK (1996) Autoradiographic study on the pharmacological characteristics of [3H]3-OH-PCP binding sites in rat brain. Eur J Pharmacol 310:243–255
Thornton S, Lisbon D, Lin T, Gerona R (2017) Beyond ketamine and phencyclidine: analytically confirmed use of multiple novel arylcyclohexylamines. J Psychoactive Drugs 49:289–293
Thurkauf A, de Costa B, Yamaguchi S, Mattson MV, Jacobson AE, Rice KC, Rogawski MA (1990) Synthesis and anticonvulsant activity of 1-phenylcyclohexylamine analogues. J Med Chem 33:1452–1458
Tikhonova IG, Baskin II, Palyulin VA, Zefirov NS (2004) 3D-model of the ion channel of NMDA receptor: qualitative and quantitative modeling of the blocker binding. Dokl Biochem Biophys 396:181–186
Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62:405–496
Vaupel DB (1983) Phencyclidine studies in the dog. Pharmacology of PCP, profiles of eight analogues abused by man and the similarity of PCP to the opioid NANM (N-allylnormetazocine or SKF 10,047). In: Domino EF (ed) Phencyclidine and related arylcyclohexylamines: present and future applications. NPP Books, Ann Arbor, pp 347–367
Vaupel DB, McCoun D, Cone EJ (1984) Phencyclidine analogs and precursors: rotarod and lethal dose studies in the mouse. J Pharmacol Exp Ther 230:20–27
Vignon J, Vincent JP, Bidard JN, Kamenka JM, Geneste P, Monier S, Lazdunski M (1982) Biochemical properties of the brain phencyclidine receptor. Eur J Pharmacol 81:531–542
Vignon J, Cerruti C, Chaudieu I, Pinet V, Chicheportiche M, Kamenka JM, Chicheportiche R (1988) Interaction of molecules in the phencyclidine series with the dopamine uptake system: correlation with their binding properties to the phencyclidine receptor. Binding properties of [3H]BTCP, a new PCP analog, to the dopamine uptake complex. In: Domino EF, Kamenka JM (eds) Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp 199–208
Walberg CB, McCarron MM, Schulze BN (1983) Quantitation of phencyclidine in serum by enzyme immunoassay: results in 405 patients. J Anal Toxicol 7:106–110
Wall ME, Brine DR, Jeffcoat AR, Cook CE (1981) Phencyclidine metabolism and disposition in man following a 100 μg intravenous dose. Res Commun Subst Abuse 2:161–172
Wallach JV (2014) Structure activity relationship (SAR) studies of arylcyclohexylamines as N-methyl-D-aspartate receptor antagonists. PhD dissertation, University of the Sciences, Philadelphia
Wallach J, De Paoli G, Adejare A, Brandt SD (2014) Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues. Drug Test Anal 6:633–650
Wallach J, Kang H, Colestock T, Morris H, Bortolotto ZA, Collingridge GL, Lodge D, Halberstadt AL, Brandt SD, Adejare A (2016a) Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One 11:e0157021
Wallach J, Colestock T, Cicali B, Elliott SP, Kavanagh PV, Adejare A, Dempster NM, Brandt SD (2016b) Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines. Drug Test Anal 8:801–815
Zarantonello P, Bettini E, Paio A, Simoncelli C, Terreni S, Cardullo F (2011) Novel analogues of ketamine and phencyclidine as NMDA receptor antagonists. Bioorg Med Chem Lett 21:2059–2063
Zidkova M, Hlozek T, Balik M, Kopecky O, Tesinsky P, Svanda J, Balikova MA (2017) Two cases of non-fatal intoxication with a novel street hallucinogen: 3-methoxy-phencyclidine. J Anal Toxicol 41:350–354
Zukin SR, Zukin RS (1979) Specific [3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci U S A 76:5372–5376
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Wallach, J., Brandt, S.D. (2018). Phencyclidine-Based New Psychoactive Substances. In: Maurer, H., Brandt, S. (eds) New Psychoactive Substances . Handbook of Experimental Pharmacology, vol 252. Springer, Cham. https://doi.org/10.1007/164_2018_124
Download citation
DOI: https://doi.org/10.1007/164_2018_124
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-10560-0
Online ISBN: 978-3-030-10561-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)